Teamwork Financial Advisors LLC Purchases 399 Shares of Abbott Laboratories $ABT

Teamwork Financial Advisors LLC boosted its position in Abbott Laboratories (NYSE:ABT) by 1.6% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 26,139 shares of the healthcare product maker’s stock after purchasing an additional 399 shares during the period. Teamwork Financial Advisors LLC’s holdings in Abbott Laboratories were worth $3,555,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ABT. Hughes Financial Services LLC bought a new stake in Abbott Laboratories in the 1st quarter worth about $27,000. Abound Financial LLC bought a new position in shares of Abbott Laboratories during the 1st quarter valued at approximately $28,000. Elequin Capital LP bought a new position in shares of Abbott Laboratories during the 1st quarter valued at approximately $30,000. Wormser Freres Gestion bought a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $32,000. Finally, JCIC Asset Management Inc. bought a new position in shares of Abbott Laboratories during the 1st quarter valued at approximately $32,000. 75.18% of the stock is owned by institutional investors.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Up 1.0%

ABT opened at $133.92 on Friday. The company has a 50 day moving average of $130.41 and a 200 day moving average of $131.29. The company has a market cap of $233.08 billion, a PE ratio of 16.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period last year, the firm earned $1.14 EPS. Abbott Laboratories’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ABT. Royal Bank Of Canada increased their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and increased their target price for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Leerink Partners began coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 target price for the company. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Finally, Wells Fargo & Company cut their price objective on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.